| 000 | 01892 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250514155823.0 | ||
| 264 | 0 | _c20031124 | |
| 008 | 200311s 0 0 eng d | ||
| 022 | _a1537-6591 | ||
| 024 | 7 |
_a10.1086/377734 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMayxay, Mayfong | |
| 245 | 0 | 0 |
_aChloroquine versus sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum malaria in Savannakhet Province, Lao People's Democratic Republic: an assessment of national antimalarial drug recommendations. _h[electronic resource] |
| 260 |
_bClinical infectious diseases : an official publication of the Infectious Diseases Society of America _cOct 2003 |
||
| 300 |
_a1021-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntimalarials _xtherapeutic use |
| 650 | 0 | 4 |
_aChloroquine _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealth Planning Guidelines |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLaos _xepidemiology |
| 650 | 0 | 4 |
_aMalaria, Falciparum _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPyrimethamine _xtherapeutic use |
| 650 | 0 | 4 |
_aSulfadoxine _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aNewton, Paul N | |
| 700 | 1 | _aKhanthavong, Maniphono | |
| 700 | 1 | _aTiengkham, Pongvongsa | |
| 700 | 1 | _aPhetsouvanh, Rattanaxay | |
| 700 | 1 | _aPhompida, Samlane | |
| 700 | 1 | _aBrockman, Alan | |
| 700 | 1 | _aWhite, Nicholas J | |
| 773 | 0 |
_tClinical infectious diseases : an official publication of the Infectious Diseases Society of America _gvol. 37 _gno. 8 _gp. 1021-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1086/377734 _zAvailable from publisher's website |
| 999 |
_c14283695 _d14283695 |
||